Click here to download the agenda. Tweet your questions using the hashtag #MJNeuroSummit . Please note all times listed are EDT.

Day 1: March 22, 2016

8:00 – 9:00 a.m. Registration
9:00 – 9:30 a.m. Welcome and National Institutes of Health (NIH) Director Remarks
Nora D. Volkow, M.D., Director
National Institute on Drug Abuse (NIDA)

Walter J. Koroshetz, M.D., Director
National Institute of Neurological Disorders and Stroke (NINDS)
9:30 – 11:00 a.m. Understanding the Endocannabinoid System

David Shurtleff, Ph.D.
National Center for Complementary and Integrative Health (NCCIH)

Aidan Hampson, Ph.D.

The Endocannabinoid System – An Introduction
Benjamin Cravatt, Ph.D. - BIO
The Scripps Research Institute

Cannabinoid Receptors: Where They Are and What They Do
Ken Mackie, M.D. – BIO
Indiana University

Therapeutic Potential of the Cannabinoid System
Daniele Piomelli, Ph.D. – BIO
University of California, Irvine
11:00 – 11:15 a.m. Break
11:15 – 12:45 p.m. Brain Development and Function

Steve Grant, Ph.D.

Does Marijuana Harm The Brain?
Kent Hutchison, Ph.D. - BIO
University of Colorado Boulder

Brain Development and Function: Adolescent Marijuana use: Influence on Learning, Memory and Brain Changes
Susan Tapert, Ph.D. - BIO
University of California, San Diego

Cannabis Use and Cognitive Impairment
Madeline Meier, Ph.D. - BIO
Arizona State University
12:45 – 2:00 p.m. Scientific Poster Session
Lunch on Your Own

2:00 – 2:10 p.m.
Office of National Drug Control Policy Remarks

Michael Botticelli, Director of National Drug Control Policy
Office of National Drug Control Policy (ONDCP)
2:10 – 2:15 p.m. Summit Host Remarks

Peggy Murray, Ph.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

2:15 – 3:45 p.m. Psychosis, Addiction, and Alcohol Interactions

David Goldman, M.D.

Wilson M. Compton, M.D., M.P.E.

The Association Between Cannabis Use and Psychosis: Clinical, Epidemiological, and Neuroscience Perspectives
Anne Eden Evins, M.D., M.P.H. - BIO
Massachusetts General Hospital

Addiction to Cannabis Phenomenology, Prevalence, Outcomes & Probability
Alan Budney, Ph.D. - BIO
Geisel School of Medicine at Dartmouth

Marijuana and Alcohol Interactions: Co-morbidity, Consequences and Mechanisms
Larry Parsons, Ph.D. - BIO
The Scripps Research Institute
3:45 – 4:00 p.m. Break
4:00 – 5:30 p.m. Therapeutic Potential: Epilepsy and Multiple Sclerosis

Alan L. Willard, Ph.D.

Mechanisms of Cannabinoid Signaling in Epilepsy
Ivan Soltesz, Ph.D. - BIO
Stanford University

Cannabinoids for Treatment of Pediatric Epilepsy: The Hype and the Evidence
Amy Brooks-Kayal, M.D. - BIO
Children’s Hospital Colorado

Multiple Sclerosis and Cannabinoids: Therapeutic Potential
David Gloss, M.D., M.P.H. - BIO
Charleston Area Medical Center
5:30 p.m. Adjournment

Day 2: March 23, 2016

9:00 – 9:15 a.m. Welcome and NIH Director Remarks

Nora D. Volkow, M.D., Director

Francis S. Collins, M.D., Ph.D., Director
9:15 – 9:45 a.m. Psychomotor Performance and Detection
Steve Gust, Ph.D.

Effects of Cannabis on Human Psychomotor Performance
Marilyn Huestis, Ph.D. - BIO
University of Maryland School of Medicine
9:45 – 11:45 a.m. Therapeutic Potential: Pain and PTSD/Anxiety

John Williamson, Ph.D.

Susan Borja, Ph.D.
National Institute of Mental Health (NIMH)

Harnessing the Therapeutic Potential of the Endocannabinoid Signaling System to Suppress Pain
Andrea G. Hohmann, Ph.D. - BIO
Indiana University

The Therapeutic Potential of Cannabis in the Treatment of Neuropathic Pain
Barth Wilsey, M.D. - BIO
University of California, San Diego

Cannabinoids and the Processing of Fear and Anxiety: Preclinical Studies
Cecilia Hillard, Ph.D. - BIO
Medical College of Wisconsin

What is the Therapeutic Potential of Cannabis in PTSD & Anxiety Disorder Treatment?: Evidence from Human Studies
Christine Rabinak, Ph.D. - BIO
Wayne State University
11:45 – 1:00 p.m. Scientific Poster Session
Lunch on Your Own
1:00 – 1:15 p.m. Summit Host Remarks

Bruce Cuthbert, Ph.D., Acting Director

Josephine P. Briggs, M.D., Director
1:15 – 3:15 p.m. Policy Research: Challenges and Future Directions

Susan Weiss, Ph.D.

Michael Hilton, Ph.D.

A Cannabis Research Agenda for Policy Design: What Do We Need to Know?
Mark Kleiman, Ph.D., M.P.P. - BIO
NYU Marron Institute of Urban Management
BOTEC Analysis Corporation

The Effects of Liberalizing Marijuana Policies on Use & Harms: Why Research Has Not Told Us Much
Rosalie Liccardo Pacula, Ph.D. - BIO
RAND Corporation

Regulating Retail Marijuana: Lessons Learned from Tobacco Control
Stanton Glantz, Ph.D. - BIO
University of California, San Francisco

Policy Surveillance Resources
Rosalie Liccardo Pacula, Ph.D. - BIO
RAND Corporation

Recreational Use of Cannabis to be Included in Alcohol Policy Information System
Michael Hilton, Ph.D.
3:15 – 4:00 p.m. Concluding Remarks

Robert M. Califf, M.D., Commissioner of Food and Drugs
U.S. Food and Drug Administration

Nora D. Volkow, M.D., Director
4:00 p.m. Adjournment


*Please note that hard copies of the agenda will not be provided on site. If you prefer a printed copy of the agenda, please print it and bring it with you.